Vera Therapeutics, Inc. (VERA) — Analyst outlook / Analyst consensus target is. Based on 14 analyst ratings, the consensus is bullish — 1 Strong Buy, 12 Buy, 1 Hold.
The consensus price target is $77.60 (low: $33.00, high: $97.00), representing an upside of 74.9% from the current price $44.36.
Analysts estimate Earnings Per Share (EPS) of $-2.87 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.75 vs est $-2.87 (beat +4.1%). 2025: actual $-4.66 vs est $-4.58 (missed -1.7%). Analyst accuracy: 97%.
VERA Stock — 12-Month Price Forecast
$77.60
▲ +74.93% Upside
Average Price Target
Based on 14 Wall Street analysts offering 12-month price targets for Vera Therapeutics, Inc., the average price target is $77.60, with a high forecast of $97.00, and a low forecast of $33.00.
The average price target represents a +74.93% change from the last price of $44.36.
Highest Price Target
$97.00
Average Price Target
$77.60
Lowest Price Target
$33.00
VERA Analyst Ratings
Buy
Based on 14 analysts giving stock ratings to Vera Therapeutics, Inc. in the past 3 months
EPS Estimates — VERA
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.75
vs Est –$2.87
▲ 4.2% off
2025
Actual –$4.66
vs Est –$4.58
▼ 1.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — VERA
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
